Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

14 of 17 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

Asan Medical Center 1

No dated milestone in 2025 to 2030

Ascentage Pharma 1

No dated milestone in 2025 to 2030

Bayer 1

RegorafenibApproved
No dated milestone in 2025 to 2030

Blueprint Medicines 1

AvapritinibApproved
No dated milestone in 2025 to 2030

Centre Leon Berard 1

No dated milestone in 2025 to 2030

Cogent Biosciences 1

FDA PDUFA target action date (GIST, with sunitinib), Nov 30, 2026

Deciphera Pharmaceuticals 2

RipretinibApproved
No dated milestone in 2025 to 2030
DCC-3009Phase 1/2
No dated milestone in 2025 to 2030

GSK 1

No dated milestone in 2025 to 2030

Merck 1

BelzutifanPhase 2
No dated milestone in 2025 to 2030

Ningbo Newbay Technology Development 1

NB003Phase 2/3
No dated milestone in 2025 to 2030

Novartis 1

ImatinibApproved
No dated milestone in 2025 to 2030

Peking University 1

No dated milestone in 2025 to 2030

Pfizer 1

SunitinibApproved
No dated milestone in 2025 to 2030